Krilogy Financial LLC Has $1.51 Million Position in Pfizer Inc. $PFE

by · The Cerbat Gem

Krilogy Financial LLC raised its position in Pfizer Inc. (NYSE:PFE – Free Report) by 22.9% during the second quarter, HoldingsChannel.com reports. The firm owned 62,220 shares of the biopharmaceutical company’s stock after buying an additional 11,590 shares during the quarter. Krilogy Financial LLC’s holdings in Pfizer were worth $1,508,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Fragasso Financial Advisors Inc raised its position in Pfizer by 2.2% during the second quarter. Fragasso Financial Advisors Inc now owns 22,460 shares of the biopharmaceutical company’s stock valued at $544,000 after acquiring an additional 480 shares in the last quarter. Fiduciary Alliance LLC increased its stake in shares of Pfizer by 935.2% during the 2nd quarter. Fiduciary Alliance LLC now owns 99,220 shares of the biopharmaceutical company’s stock worth $2,405,000 after purchasing an additional 89,635 shares during the last quarter. First Bank & Trust raised its holdings in shares of Pfizer by 2.5% during the 2nd quarter. First Bank & Trust now owns 71,216 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 1,738 shares in the last quarter. OLD Republic International Corp lifted its stake in shares of Pfizer by 20.9% in the 2nd quarter. OLD Republic International Corp now owns 1,963,700 shares of the biopharmaceutical company’s stock valued at $47,600,000 after purchasing an additional 340,000 shares during the last quarter. Finally, Triumph Capital Management boosted its holdings in Pfizer by 109.6% in the second quarter. Triumph Capital Management now owns 18,102 shares of the biopharmaceutical company’s stock worth $439,000 after purchasing an additional 9,466 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $23.88 on Wednesday. The firm has a market cap of $135.77 billion, a P/E ratio of 12.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The firm’s 50-day simple moving average is $24.73 and its 200-day simple moving average is $24.25. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

Several research firms have weighed in on PFE. Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley upped their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Finally, Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.12.

Read Our Latest Stock Report on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).